Patents Issued in September 15, 2020
-
Patent number: 10772916Abstract: Systems and methods are provided for deriving a platelet product from a plurality of buffy coats. A plurality of buffy coats are separately collected, for example, using a conventional floor centrifuge. Plasma and/or a platelet additive solution may be added to the buffy coats. The buffy coats are pooled into a container and conveyed into a centrifuge or are sequentially conveyed into the centrifuge without being pooled, where they are continuously processed to separate platelets from the other cellular blood components. The separated platelets are conveyed out of the centrifuge as a platelet product, which may be passed through a leukocyte removal filter to reduce the white blood cell content of the platelet product. By continuously separating the buffy coats, fewer buffy coats are required to produce a single-dose platelet product, while also allowing for the derivation and collection of a plurality of single-dose platelet products.Type: GrantFiled: September 15, 2017Date of Patent: September 15, 2020Assignee: Fenwal, Inc.Inventors: Kyungyoon Min, Benjamin E. Kusters, Richard I. Brown
-
Patent number: 10772917Abstract: Provided herein are therapies, and methods using that therapy, in the treatment of one or more of Type 2 diabetes (T2D), obesity, glucose intolerance and insulin resistance or to control weight gain in subjects. In particular, the subject may be candidates for treatment with one or more small molecule anti-diabetic drugs and the therapy may include implanting a population of pancreatic endocrine progenitor cells into the subject, where the cells are allowed to mature in vivo to produce a population.Type: GrantFiled: March 11, 2016Date of Patent: September 15, 2020Assignee: CCS VENTURES LIMITEDInventors: Timothy J. Kieffer, Jennifer E. Bruin
-
Patent number: 10772918Abstract: Methods are provided herein for preventing, delaying the onset of or reducing the progression of colorectal tumorigenesis in a subject identified as at risk of colorectal tumorigenesis, comprising adjusting the composition of gut microbiota in the subject via administering to the subject a composition comprising Bacteroides bacteria or administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising zwitterionic polysaccharide (ZPS). In another aspect, methods are provided for treating or ameliorating a colorectal cancer in a subject, comprising adjusting the composition of gut microbiota in the subject having the colorectal cancer. In a further aspect, methods are provided for relieving gastrointestinal (GI) distress of a subject having a colorectal condition, comprising: determining the colorectal condition of the subject; and relieving GI distress in the subject by adjusting the composition of gut microbiota in the subject.Type: GrantFiled: July 17, 2019Date of Patent: September 15, 2020Assignee: California Institute of TechnologyInventors: Sarkis K. Mazmanian, Yunkyung Lee
-
Patent number: 10772919Abstract: The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.Type: GrantFiled: June 12, 2019Date of Patent: September 15, 2020Assignee: Crestovo Holdings LLCInventor: Thomas J. Borody
-
Patent number: 10772920Abstract: The present invention relates to an extracellular polysaccharide produced by Ceriporia lacerata, a culture medium of Ceriporia lacerata hyphae including the extracellular polysaccharide, a composition for immunoregulation containing, as an active ingredient, dried powder of the hyphae culture medium or an extract of the hyphae culture medium, a pharmaceutical composition for preventing or treating an immune disease, and a health food for immunoregulation. The composition of the present invention has an excellent effect on immune enhancement and overactive immune response inhibition.Type: GrantFiled: July 22, 2016Date of Patent: September 15, 2020Assignee: FUGENBIO CO., LTD.Inventor: Yoon Soo Kim
-
Patent number: 10772921Abstract: A device for high pressure spray and counter-current precipitation extraction of herbal medicine is disclosed. A method for extracting herbal medicine using the device is also disclosed.Type: GrantFiled: June 21, 2019Date of Patent: September 15, 2020Assignee: SHAANXI UNIVERSITY OF SCIENCE AND TECHNOLOGYInventors: Chengyuan Liang, Nan Hui, Juan Li, Guaiping Qiao, Yonghong Tang, Gennian Mao, Han Li, Bin Tian, Qianqian Zhao, Yongbo Wang, Dan Yang, Hanyang Liu
-
Patent number: 10772922Abstract: Provided is a method of treating or preventing adenovirus and enterovirus infection by administering an antiviral composition that contains an Echinacea purpurea extract, a Salvia miltiorrhiza extract, or combinations thereof. The antiviral composition blocks adenoviruses and enterovirus infection through virucidal activity against adenovirus and inhibition of adenovirus and enterovirus attachment to and penetration into cells. Also provided is a method of preparing the antiviral composition.Type: GrantFiled: November 3, 2017Date of Patent: September 15, 2020Assignees: NATIONAL TAIWAN UNIVERSITY, TAICHUNG DISTRICT AGRICULTURAL RESEARCH AND EXTENSION STATION, COUNCIL OF AGRICULTURE, EXECUTIVE YUANInventors: Luan-Yin Chang, Yu-Hsin Chen
-
Patent number: 10772923Abstract: A composition containing cinnamon extract is provided to increase lean muscle mass in a subject. Also described is a method of increasing lean muscle mass in a subject through the administration of the cinnamon extract. In some aspects, a daily dose of 10-1,000 mg of the cinnamon extract supplement is administered to the subject for a period of 6 weeks to 6 months.Type: GrantFiled: June 6, 2017Date of Patent: September 15, 2020Assignee: IN Ingredients, Inc.Inventors: Timothy Romero, Peter Miller
-
Patent number: 10772924Abstract: The present disclosure relates to health benefits of Chardonnay seed products.Type: GrantFiled: September 28, 2018Date of Patent: September 15, 2020Assignees: SONOMACEUTICALS, LLC, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTUREInventors: Torey James Arvik, Rebecca Susan Lipson, Wallace H. Yokoyama
-
Patent number: 10772925Abstract: The present invention relates to a composition comprising a dry preparation of Alpinia galanga (L.) Willd (Zingiberaceae) or Alpinia conchigera Griff and a plant extract comprising compounds with anti-oxidative activity, such as an extract of Punica granatum. Also disclosed herein is a method of improving semen quality by administering said composition to a male subject in need thereof.Type: GrantFiled: June 6, 2014Date of Patent: September 15, 2020Assignee: NERTHUS APSInventors: Ina Giversen, Henrik Jakobsen
-
Patent number: 10772926Abstract: The invention is directed to natural drug compositions comprising turmeric, boswellia and ginger. Methods for the use of the inventive drug compositions in the treatment of inflammatory disorders and melanoma are within the scope of the invention.Type: GrantFiled: December 1, 2017Date of Patent: September 15, 2020Assignee: Nutragen Health Innovations, Inc.Inventor: Bruce L. Howe
-
Patent number: 10772927Abstract: The present invention relates to the use of a casein hydrolysate as an antiviral agent for the treatment of opportunistic virus infections, especially herpesvirus and human papillomavirus. This casein hydrolysate has an application in both the therapeutic treatment of established symptoms and the prevention of the infection or the reactivation of a latent infection by an opportunistic virus. The casein hydrolysate of the present invention is effective for the prevention of opportunistic virus infections in individuals with weakened immune system.Type: GrantFiled: February 17, 2015Date of Patent: September 15, 2020Assignee: NTD Labs, S.L.Inventors: Pere Adell Winkler, Guillermo Lopez Zarco
-
Patent number: 10772928Abstract: Methods for treatment and diagnosis of neurological disorders such as autism and autism spectrum disorder are disclosed. Also disclosed are modulators of alternative splicing regulators SRRM4 and/or SRRM3 for treating neurological disorders. Further disclosed are agents that modulate the expression of at least one splice variant for treating neurological disorders. Mouse models of neurological disorders having increased or decreased expression of SRRM4 and/or SRRM3 are also disclosed.Type: GrantFiled: December 15, 2015Date of Patent: September 15, 2020Assignees: The Governing Council of the University of Toronto, Sinai Health SystemInventors: Benjamin J. Blencowe, Mathieu Quesnel-Vallieres, Manuel Irimia, Bushra Raj, Sabine P. Cordes
-
Patent number: 10772929Abstract: Method of use of peptides and their analogs in the treatment of acute pancreatitis are described. The disclosed peptides and analogs can significantly lower the elevated blood amylase and lipase levels caused by acute pancreatitis, reduce the degree of injury observed in pancreatic histopathology caused by pancreatitis, and significantly lower the mortality rate of acute pancreatitis.Type: GrantFiled: May 11, 2017Date of Patent: September 15, 2020Assignee: SHENZHEN HIGHTIDE BIOPHARMACEUTICAL, LTD.Inventors: Liping Liu, Ru Bai
-
Patent number: 10772930Abstract: The present invention relates to an isolated bacterium from the genus Pseudoalteromonas for its use as a probiotic, the use of said strain as a preservative, cyclolipopeptides which may be obtained from this bacterium, a composition comprising at least such a cyclolipopeptide, as well as to their uses.Type: GrantFiled: March 27, 2018Date of Patent: September 15, 2020Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.), UNIVERSITE DE RENNES 1, UNIVERSITE DE BRETAGNE OCCIDENTALEInventors: Florie Desriac, Yannick Fleury, Patrick Le Chevalier, Delphine Destoumieux, Matthieu Simon
-
Patent number: 10772931Abstract: Compositions and methods are provided for treating a patient suffering from a disease associated with endothelial dysfunction by administering to the patient a pharmaceutical composition containing an effective amount of a synthetic collagen binding peptidoglycan.Type: GrantFiled: April 24, 2015Date of Patent: September 15, 2020Assignee: Purdue Research FoundationInventors: Alyssa Panitch, Rebecca Scott
-
Patent number: 10772932Abstract: A medicament for use in treating cardiovascular and cerebrovascular diseases, the medicament includes a marine algal glycoprotein.Type: GrantFiled: January 20, 2017Date of Patent: September 15, 2020Assignee: SHANDONG ZHONGHAI PHARMACEUTICAL CO. LTDInventors: Baozhen Xu, Qian Cheng, Long Cheng
-
Patent number: 10772933Abstract: A medicament for use in treating tuberculosis, the medicament is a glycoprotein, a mixture of polysaccharide and protein, a polypeptide or a protein.Type: GrantFiled: January 20, 2017Date of Patent: September 15, 2020Assignee: SHANDONG ZHONGHAI PHARMACEUTICAL CO. LTDInventors: Baozhen Xu, Qian Cheng, Long Cheng
-
Patent number: 10772934Abstract: This invention relates to novel compositions comprising analogs of naturally occurring polypeptides, wherein the analog comprises an ?-amino acid and at least one ?-amino acid. Administration of the compositions may be used for effecting treatment or prevention of a plurality of disease states caused by dysfunctional biochemical or biological pathways. The compositions and methods of this invention are particularly useful to identify novel therapeutic modulators of in-vivo receptor activity with extended half-lives and relevant bioactivity as compared to the naturally translated polypeptides upon which the analogs are derived.Type: GrantFiled: August 31, 2017Date of Patent: September 15, 2020Assignee: LONGEVITY BIOTECH, INC.Inventors: Scott J. Shandler, Samuel H. Gellman
-
Patent number: 10772935Abstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.Type: GrantFiled: June 29, 2018Date of Patent: September 15, 2020Assignee: MannKind CorporationInventors: Anders Hasager Boss, Richard Petrucci, Campbell Howard, Alfred Mann
-
Patent number: 10772936Abstract: The present invention provides modified von Willebrand Factor molecules, methods for their preparation and uses thereof. The invention further provides pharmaceutical compositions for treating coagulation disorders.Type: GrantFiled: May 20, 2016Date of Patent: September 15, 2020Assignee: CSL BEHRING LENGNAU AGInventors: Stefan Schulte, Hans-Wilhelm Beltz, Sabine Pestel, Thomas Weimer, Matthias Pelzing
-
Patent number: 10772937Abstract: The invention provides compositions containing hemoglobin, particularly PEGylated hemoglobin. The PEGylated hemoglobin molecule is capable of transferring oxygen or carbon monoxide bound thereto to a tissue with which it is in proximity. Exemplary PEGylated hemoglobin formulations of the invention are virally inactivated. Various compositions of the invention include deoxygenated hemoglobin, which may be conjugated with one or more water-soluble polymer. PEGylated hemoglobin includes those species in which the iron atom of the hemoglobin molecule is not bound to oxygen or any other species, and hemoglobin molecules in which a species other than oxygen, e.g., carbon monoxide, is bound to the iron atom. The compositions of the invention are formulated as hypo-, iso- or hypertonic solutions of the PEGylated hemoglobin. The compositions are of use to treat and/or ameliorate disease, injury and insult by providing for the oxygenation of tissues and/organs.Type: GrantFiled: August 22, 2018Date of Patent: September 15, 2020Assignee: Prolong Pharmaceuticals, LLCInventors: Abraham Abuchowski, Steven Sloshberg, Keith O'Hare
-
Patent number: 10772938Abstract: The present invention includes methods and compositions for increasing longevity of a cell and increasing cellular resistance to stress. In certain embodiments, the invention includes a method to induce gene expression of a homolog of Pachytene Checkpoint 2 (pch-2) or bmk-1 gene. The present invention also includes methods to treat oxidative stress or induce cellular death or apoptosis by administering a composition comprising a modulator of pch-2 or bmk-1 homolog gene expression.Type: GrantFiled: January 13, 2016Date of Patent: September 15, 2020Assignee: Yale UniversityInventors: Laura E. Niklason, Xiangru Xu, Hong Qian
-
Patent number: 10772939Abstract: Provided are fragments of human p97 (melanotransferrin) polypeptides having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, conjugates comprising the p97 fragments, and related methods of use thereof, for instance, to facilitate delivery of therapeutic or diagnostic agents across the BBB.Type: GrantFiled: May 8, 2018Date of Patent: September 15, 2020Assignee: Bioasis Technologies, Inc.Inventors: Timothy Z. Vitalis, Reinhard Gabathuler
-
Patent number: 10772940Abstract: The presently-disclosed subject matter includes isolated polypeptides that comprise a butyrylcholinestrase (BChE) polypeptide and a second polypeptide. The BChE polypeptide as well as the second polypeptide can be variants and/or fragments thereof. The presently-disclosed subject matter also includes a pharmaceutical composition that comprises the present isolated polypeptide and a suitable pharmaceutical carrier. Further still, methods are provided for treating cocaine-induced conditions, and comprise administering the isolated polypeptide and/or pharmaceutical compositions thereof to an individual.Type: GrantFiled: December 11, 2013Date of Patent: September 15, 2020Assignee: University of Kentucky Research FoundationInventors: Chang-Guo Zhan, Fang Zheng, Hsin-Hsiung Tai, Xiabin Chen, Liu Xue, Shurong Hou
-
Patent number: 10772941Abstract: The present invention relates to a composition for use in low dose artificial insemination and to a process for artificial insemination of a female mammal using a dose of sperm originating from a male mammal of the same species that is significantly lower than necessary in the absence of the composition. The preferred female mammal is a sow (Sus scrofa), and preferably the composition is for use in artificial uterine insemination, and the process for artificial insemination preferably is uterine insemination.Type: GrantFiled: July 14, 2016Date of Patent: September 15, 2020Assignee: IMV TECHNOLOGIESInventor: Eric Schmitt
-
Patent number: 10772942Abstract: The present invention provides, among other things, pre-lyophilization formulations, reconstituted formulations, and lyophilate powder compositions comprising a Factor IX (FIX) polypeptide. The present invention also provides lyophilization methods for producing lyophilate powder comprising a FIX polypeptide. The present invention is directed to a pre-lyophilization formulation comprising: (a) a Factor IX (FIX) polypeptide having FIX coagulation activity; (b) a buffering agent; (c) a stabilizing agent; (d) a bulking agent; and (e) a surfactant, wherein the formulation has a fill volume of less than about 5 mL, and wherein each of (a)-(e) are at an amount per vial (mg/vial) sufficient to allow (1) improved stability of the FIX polypeptide when lyophilized.Type: GrantFiled: March 24, 2015Date of Patent: September 15, 2020Assignee: Bioverativ Therapeutics Inc.Inventors: Brian M. Thome, Cherie Parkhurst-Lang, Brandon W. Leveille
-
Liquid formulation containing botulinum toxin and stabilizing agent, and preparation method therefor
Patent number: 10772943Abstract: The present invention relates to a liquid formulation containing botulinum toxin and stabilizing agent, and preparation method therefor. A liquid formulation containing botulinum toxin and stabilizing agent according to the present invention be can be easily stored and distributed. It was proved a significant effect on the stabilization of botulinum toxin under suitable conditions according to the temperature and pH of the human body. Thus, it is expected that the pharmaceutical composition of the present invention will greatly contribute to the safe and convenient medical use of botulinum toxin.Type: GrantFiled: August 28, 2017Date of Patent: September 15, 2020Assignee: HUGEL INC.Inventors: Chee Gun Lee, Ji Hyun Oum -
Patent number: 10772944Abstract: The present invention relates to a composition comprising Bacterial Ghosts, optionally an active agent, and a pharmaceutically acceptable carrier and/or excipient for use in the treatment of cancer.Type: GrantFiled: January 20, 2017Date of Patent: September 15, 2020Assignee: BIRD-C GMBHInventors: Werner Lubitz, Pavol Kudela, Marek Sramko
-
Patent number: 10772945Abstract: The invention relates to a novel VHH construct which can be bounded by a complete antibody without impairment of the antigen binding properties of the VHH construct being impaired. The invention also relates to an antibody construct comprising a VHH construct of this type and a kit, as well as the use thereof in immunodiagnostics or in the area of therapeutics. With the invention, among other things, it is possible to direct the existing immunity of a patient toward a different antigen.Type: GrantFiled: April 11, 2016Date of Patent: September 15, 2020Assignee: PRECLINICS GES. F. PRAEKLINISCHE FORSCHUNG MBHInventors: Jonas Fuener, Angelo Bolchi, Erik Schliebs, Simone Ottonello
-
Patent number: 10772946Abstract: The invention relates to a conjugate of a saccharide covalently bound to a carrier protein, wherein the saccharide comprises repetitive units of 1,5 ribitol phosphate in which all the ribitol residues are substituted by N-acetyl D-glucosaminyl residues at the 4-position, and wherein said N-acetyl D-glucosaminyl residues are exclusively in anomeric configuration ? or are exclusively in anomeric configuration ? and wherein the carrier protein provides at least one epitope to the conjugate which is recognized by T helper lymphocytes.Type: GrantFiled: October 13, 2016Date of Patent: September 15, 2020Assignee: SANOFI PASTEURInventors: Pierre-Alexandre Driguez, Nathalie Guillo, Bachra Rokbi, Noëlle Mistretta, Philippe Talaga
-
Patent number: 10772947Abstract: The invention provides human papillomavirus (HPV) antigen formulations which show increased antigen stability. More specifically, the invention provides stable HPV formulations comprising HPV virus-like particles (VLPs) bound to an aluminum salt adjuvant and further comprise a combination of sucrose and mannitol. The vaccine formulations of the invention are stable following freeze-thaw and freeze-drying. Also provided are lyophilized and frozen HPV vaccine formulations comprising HPV VLPs of at least one HPV type adsorbed onto an aluminum salt adjuvant, sucrose, and mannitol. Methods of making the stable vaccine formulations of the invention are also provided.Type: GrantFiled: December 14, 2016Date of Patent: September 15, 2020Assignee: Merck Sharp & Dohme Corp.Inventors: Ramesh V. Chintala, Akhilesh Bhambhani
-
Patent number: 10772948Abstract: The present invention provides compositions directed to recombinant flavivirus E glycoprotein ectodomain dimers for use in diagnostic and immunotherapeutic methods.Type: GrantFiled: September 20, 2016Date of Patent: September 15, 2020Assignee: The University of North Carolina at Chapel HillInventors: Stefan Metz, Aravinda Desilva, Michael Miley
-
Patent number: 10772949Abstract: Specific Dengue virus glycoprotein subunit E DIII variants and their uses in preventing and treating Dengue virus infection are disclosed.Type: GrantFiled: February 13, 2017Date of Patent: September 15, 2020Assignee: Albert Einstein College of MedicineInventors: Jonathan R. Lai, Margaret C. Kielian, Julia C. Frei
-
Patent number: 10772950Abstract: The present invention relates to an immunogenic composition comprising: a) a modified live H3 virus of swine influenza, and b) a modified live H1 virus of swine influenza. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by swine influenza virus in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.Type: GrantFiled: June 22, 2018Date of Patent: September 15, 2020Inventors: Marc Allan Eichmeyer, Wesley Scott Johnson, Eric Martin Vaughn, Michelle L. Walz
-
Patent number: 10772951Abstract: The present disclosure concerns an oncolytic virus for the treatment of cancer, such as in brain cancer, for example glioblastoma. The oncolytic virus may exhibit reduced levels of neurotoxicity. The oncolytic virus may be an isolated viral particle capable of producing a cDNA polynucleotide that includes a sequence according to SEQ ID NO: 1 when the virus is in a host cell. The oncolytic virus may be an isolated viral particle that includes an RNA polynucleotide that includes a sequence according to SEQ ID NO: 2. The oncolytic virus may be an isolated viral particle having a genome that includes open reading frames that encode: proteins having sequences comprising SEQ ID NOs: 3, 4, 5, 6 and 7; or variants thereof.Type: GrantFiled: May 16, 2016Date of Patent: September 15, 2020Assignee: CHILDREN'S HOSPITAL OF EASTERN ONTARIO RESEARCH INSTITUTE INC.Inventor: David F. Stojdl
-
Patent number: 10772952Abstract: The invention provides compositions, methods, and kits for the treatment or prevention of viral infections. The polyvalent (e.g., 2-valent) vaccines described herein incorporate computationally-optimized viral polypeptides that can increase the diversity or breadth and depth of cellular immune response in vaccinated subjects.Type: GrantFiled: June 14, 2019Date of Patent: September 15, 2020Assignees: Beth Israel Deaconess Medical Center, Inc., Triad National Security, LLCInventors: Dan H. Barouch, Bette T. Korber, William M. Fischer
-
Patent number: 10772953Abstract: Disclosed are recombinant spike ectodomain proteins, compositions, vectors, kits, and methods for inducing an immune response against avian infectious bronchitis virus (IBV). In particular, the recombinant proteins, compositions, vectors, kits, and methods relate to, include, and/or utilize a soluble, multimerized form of the (IBV) spike (S) protein ectodomain. The recombinant proteins, compositions, vectors, kits, and methods may be utilized to immunize poultry against disease associated with IBV infection or to protect poultry from IBV infection.Type: GrantFiled: August 9, 2018Date of Patent: September 15, 2020Assignee: Auburn UniversityInventors: Vicky L. van Santen, Haroldo E. Toro
-
Patent number: 10772954Abstract: The present invention relates to vaccines comprising an effective amount of at least one antigen in a water-in-oil-in-water (WOW) emulsion and an additional adjuvant, and to the methods of preparation and uses thereof.Type: GrantFiled: June 15, 2015Date of Patent: September 15, 2020Assignee: Biomune CompanyInventors: Roger H. Ruehling, Brianna Ford
-
Patent number: 10772955Abstract: The disclosed invention provides mammalian milk osteopontin and/or an active truncation or active peptide thereof for improving immune responsiveness to an infectious disease in a mammal, for example a human subject, as well as enhancing the efficacy of vaccination for the prophylactic or therapeutic treatment of an infectious disease in mammals, such as humans. The invention further provides a vaccine system, for use in the prophylactic or therapeutic treatment of an infectious disease in a mammal, comprising a vaccine and a mammalian milk osteopontin and/or an active truncation or active peptide thereof for oral administration to a mammal, as well as methods of enhancing immune resistance to an infectious disease in a mammal by administration of a vaccine and a mammalian milk osteopontin and/or an active truncation thereof.Type: GrantFiled: April 4, 2018Date of Patent: September 15, 2020Assignee: ARLA FOODS AMBAInventors: Anne Staudt Kvistgaard, Peter Langborg Wejse, Sharon Donovan, Marcia H. Monaco Siegel, Sarah S. Comstock
-
Patent number: 10772956Abstract: The present invention provides methods for reducing or eliminating a patient's need for lipoprotein apheresis therapy. The methods of the present invention comprise administering to a patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody. The methods of the present invention are useful for treating patients with hyperlipidemia and related conditions who are currently being treated with a therapeutic regimen comprising lipoprotein apheresis (e.g., LDL apheresis or Lp(a) apheresis).Type: GrantFiled: August 17, 2016Date of Patent: September 15, 2020Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Robert C. Pordy, Garen Manvelian
-
Patent number: 10772957Abstract: Methods, apparatus, and systems are provided for tracking freight. Embodiments include a tracking device for a trailer containing a load. The tracking device includes a support member, a connector, a housing and a GPS tracker configured to track the location of the load. The connector securely attaches to a container on the trailer and attaches to a seal such that the container cannot be opened without breaking the seal. The support member stabilizes the housing and protects the tracking device during transit of the load. A tracking system may implement to monitor, gather information and report on the tracking device and the load.Type: GrantFiled: July 6, 2018Date of Patent: September 15, 2020Assignee: CRC R&D, LLCInventor: Ronald H. Mains, Jr.
-
Patent number: 10772958Abstract: The present disclosure relates to anti-CD40 antibodies, such as humanized anti-CD40 antibodies, that may be used in various therapeutic, prophylactic and diagnostic methods. The antibodies generally block the ability of CD40 to bind CD154 and do so without activating the cell expressing CD40 (e.g., a B cell). The present antibodies or fragments thereof may be used to reduce complications associated with organ or tissue transplantation.Type: GrantFiled: December 27, 2018Date of Patent: September 15, 2020Assignee: Primatope Therapeutics Inc.Inventors: Bo Yu, Rijian Wang, Keith Reimann
-
Patent number: 10772959Abstract: The invention provides aqueous pharmaceutical adalimumab compositions suitable for long-term storage of adalimumab, methods of manufacture of these compositions, methods of administration, and kits containing same.Type: GrantFiled: June 29, 2018Date of Patent: September 15, 2020Assignee: Coherus Biosciences, Inc.Inventors: Mark Manning, Robert W. Payne
-
Patent number: 10772960Abstract: The invention provides aqueous pharmaceutical adalimumab compositions suitable for long-term storage of adalimumab, methods of manufacture of these compositions, methods of administration, and kits containing same.Type: GrantFiled: June 29, 2018Date of Patent: September 15, 2020Assignee: Coherus Biosciences, Inc.Inventors: Mark Manning, Robert W. Payne
-
Patent number: 10772961Abstract: The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, an histidine buffering agent such as histidine (or histidine buffer system such as histidine/imidiazolium-histidine), and a sugar stabiliser such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug.Type: GrantFiled: November 25, 2019Date of Patent: September 15, 2020Assignee: Fresenius Kabi Deutschland GmbHInventors: Gianluca Rinaldi, Silvia Fratarcangeli, Alessandra Del Rio
-
Patent number: 10772962Abstract: The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.Type: GrantFiled: August 5, 2016Date of Patent: September 15, 2020Assignees: ARVINAS OPERATIONS, INC., YALE UNIVERSITYInventors: Yimin Qian, Hanqing Dong, Jing Wang, Michael Berlin, Andrew P. Crew, Craig M. Crews
-
Patent number: 10772963Abstract: The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.Type: GrantFiled: February 25, 2019Date of Patent: September 15, 2020Assignee: Coherus Biosciences, Inc.Inventors: Mark Manning, Brian Murphy
-
Patent number: 10772964Abstract: Amino acid based polymers and polymer blends. Compositions comprising at least one amino acid based polymer or polymer blend, at least one bioactive agent, and optionally at least one filler. Additionally, compositions comprising at least one bacteriophage and at least one salt or buffer, which, for example, are in the form of a dry powder, and methods of preparing thereof are disclosed.Type: GrantFiled: June 21, 2016Date of Patent: September 15, 2020Assignee: Phagelux (Canada), Inc.Inventors: Ramaz Katsarava, David Tugushi, Vakhtang Beridze, Nancy Tawil
-
Patent number: 10772965Abstract: The present invention provides novel and advantageous compositions having a linker capable of covalently coupling one or more free thiols of an antibody. Specifically, provided herein are the molecular structures, synthetic pathways, coupling mechanisms, and applications thereof as used in an antibody-drug conjugate (ADC).Type: GrantFiled: February 14, 2018Date of Patent: September 15, 2020Assignee: RC Biotechnologies, Inc.Inventors: Changjiang Huang, Jianmin Fang, Hui Ye, Lezhi Zhang